Acorda Therapeutics, Inc.
ACOR · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -0.8% | -8.1% | -15.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60.9% | 74.4% | 68.4% | 78.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -171.6% | -8.5% | -34.7% | -42.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -215% | -55.6% | -80.5% | -65.1% |
| EPS Diluted | -203.59 | -66.9 | -195.75 | -246.4 |
| % Growth | -204.3% | 65.8% | 20.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |